Clinical Trial Update: Trial to Evaluate Safety and Efficacy of Treatment of Physician Choice (TPC) Following First-Line Treatment of Lenvatinib in Subjects With Unresectable Hepatocellular Carcinoma (uHCC) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating safety and efficacy of treatment selected by physician after first-line lenvatinib in unresectable hepatocellular carcinoma has been …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Lenvatinib (lenvatinib)

Snippet

Sponsor: Eisai Inc. | Conditions: Carcinoma, Hepatocellular | Phase 2 | Status: TERMINATED | Results posted: 2019-12-06